Ken Griffin Erasca, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Erasca, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 10,100 shares of ERAS stock, worth $25,654. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,100
Previous 3,100
225.81%
Holding current value
$25,654
Previous $7,000
285.71%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ERAS
# of Institutions
140Shares Held
229MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$49.3 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$42.8 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$41.2 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$35 Million1.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$33.8 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $310M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...